1173205-31-6

Basic information

• Product Name: 4-(3-isopropyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenylamine
• Synonyms: 4-(3-isopropyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenylamine
• CAS NO: 1173205-31-6
• Molecular Weight: 339.4
• Mol File: 1173205-31-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(3-isopropyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-isopropyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenylamine(1173205-31-6)
• EPA Substance Registry System: 4-(3-isopropyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenylamine(1173205-31-6)

Safety Data

• Hazardous Substances Data: 1173205-31-6(Hazardous Substances Data)

Upstream product

• 1173205-28-1 5-chloro-3-isopropyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidine 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 

Downstream Products

• 1173205-32-7 1-[4-(3-isopropyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin-4-ylurea 
• 1173207-66-3 1-{4-[3-(1-methylethyl)-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}urea 
• 1173207-65-2 N-[2-(dimethylamino)ethyl]-4-[({4-[3-(1-methylethyl)-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}carbamoyl)amino]benzamide 
• 1173208-03-1 1-{4-[3-(1-methylethyl)-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-(4-nitrophenyl)urea 
• 1173208-02-0 1-{4-[3-(1-methylethyl)-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-[4-(4-methylpiperazin-1-yl)phenyl]urea 

Relevant articles and documents

Lead optimization of n-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: Discovery of PKI-402

Herein we describe the identification and lead optimization of triazolopyrimidines as a novel class of potent dual PI3K/mTOR inhibitors, resulting in the discovery of 3 (PKI-402). Compound 3 exhibits good physical properties and PK parameters, low nanomolar potency against PI3KR and mTOR, and excellent inhibition of cell proliferation in several human cancer cell lines. Furthermore, in vitro and in vivo biomarker studies demonstrated the ability of 3 to shut down the PI3K/Akt pathway and induce apoptosis in cancer cells. In addition, 3 showed excellent in vivo efficacy in various human cancer xenografts, validating suppression of PI3K/mTOR signaling as a potential anticancer therapy. 2009 American Chemical Society.